Study of Esketamine Combined With Propofol to Reduce Inflammation and Improve Immune Function in Adults With Sepsis in the ICU

What this Trial Is About

Researchers are investigating the effects of esketamine combined with propofol sedation on inflammation and immune function in adults with sepsis who need mechanical ventilation in the ICU. Excessive inflammation and immune suppression contribute to early death in sepsis, so this study aims to see if esketamine can reduce inflammation and improve immune response during the acute phase. Esketamine has shown anti-inflammatory effects in previous studies and may offer cardiovascular stability during sedation. Participants are randomly assigned to one of two groups. One group receives sedation primarily with propofol adjusted to maintain a moderate sedation level, while the other group receives a single intravenous injection of esketamine followed by a continuous infusion for three days alongside propofol sedation. The esketamine infusion is delivered via pump at a fixed rate for three consecutive days to assess its effects on inflammation and immune function. Throughout the study, researchers will measure inflammatory cytokines and lymphocyte numbers in the blood at multiple time points up to 72 hours after inclusion. They will also track ICU length of stay and other health scores related to organ function and severity of illness. Safety and clinical outcomes, including hospital stay length and mortality, will be monitored for up to two years. This study lasts from initial inclusion through long-term follow-up to fully evaluate esketamines impact on sepsis patients under sedation.

Immunoinflammatory Regulation of Esketamine in Septic Patients